--- title: "Oncotelic reports $249.0 million 2025 profit that is a non-cash joint venture" url: "https://aibio.space/news/oncotelic-reports-249-0-million-2025-profit-non-cash-joint-venture/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-04-16" section: "Company Updates" tickers: "OTC:OTLC" source: "https://www.sec.gov/Archives/edgar/data/908259/000149315226016981/ex99-1.htm" summary: "The result reflects a non-cash increase of approximately $365.4 million in the fair value of the company's GMP Biotechnology investment, partly offset by a" --- By the aibio.space news desk. Sources - [Oncotelic Therapeutics, Inc. 8-K (2026-04-16)](https://www.sec.gov/Archives/edgar/data/908259/000149315226016981/ex99-1.htm) - [Oncotelic Therapeutics, Inc. 10-K (2026-04-15): business](https://www.sec.gov/Archives/edgar/data/908259/000149315226016838/form10-k.htm) - [Oncotelic Therapeutics, Inc. financial data (SEC XBRL)](https://www.sec.gov/Archives/edgar/data/908259/000149315226016838/) [OTLC](https://aibio.space/companies/oncotelic-therapeutics/) 2026-04-16 # Oncotelic reports $249.0 million 2025 profit that is a non-cash joint venture gain Tickers [OTLC](https://aibio.space/companies/oncotelic-therapeutics/) The result reflects a non-cash increase of approximately $365.4 million in the fair value of the company's GMP Biotechnology investment, partly offset by a tax provision. ## Key facts - **Company**: Oncotelic Therapeutics, Inc. (OTC: OTLC) - **News type**: Company Updates - **Primary source**: [Oncotelic Therapeutics, Inc. 8-K (2026-04-16)](https://www.sec.gov/Archives/edgar/data/908259/000149315226016981/ex99-1.htm) *An optical research setup with lenses and lasers. CC0, via rawpixel. The picture shows the field, not the companies named.* Oncotelic Therapeutics, Inc. (OTCQB: [OTLC](https://aibio.space/companies/oncotelic-therapeutics/)) reported financial results for the fiscal year ended December 31, 2025 in a press release dated April 16, 2026, filed as Exhibit 99.1 to a Form 8-K. The company reported net income after tax of approximately $249.0 million, compared with a net loss of approximately $4.8 million in the prior year. It said the result was driven mainly by a non-cash increase of approximately $365.4 million in the estimated fair value of its investment in GMP Biotechnology Limited, its joint venture. A deferred income tax provision of approximately $111.6 million partly offset that gain. The company recorded no product revenue in either year. ## The joint venture valuation The company recorded the increase in November 2025, based on an independent third-party valuation. That raised the carrying value of the investment to approximately $388.0 million. The release says the increase "does not represent product revenue or cash received," and that it reflects estimated development progress and market-based assumptions. ## Operating results General and administrative expense was $3,182,242 for 2025, compared with $376,013 for 2024. The release attributes the increase of approximately $2.8 million mainly to stock-based compensation of approximately $2.4 million, for common and preferred stock issued for services, and to approximately $0.2 million spent to settle litigation with a former employee. A loss on conversion of debt of approximately $1.0 million also weighed on results, partly offset by a favorable change in the value of derivatives on debt of approximately $0.6 million. The company reported net income attributable to Oncotelic Therapeutics, Inc. of $249,279,832, or $0.59 per basic share, compared with a loss of $0.01 per share in 2024. ## The joint venture pipeline The release describes the joint venture's programs in detail. The JV is advancing six candidates: Sapu-001 (paclitaxel), Sapu-003 (everolimus), Sapu-004 (carboplatin), Sapu-005 (palbociclib) and Sapu-006 (docetaxel), in addition to OT-101. Everolimus formulation development is complete, and a global clinical trial is enrolling participants in Australia. The company expects investigational new drug applications for palbociclib and docetaxel in 2026. The Deciparticle platform uses ultra-small amphiphilic constructs below about 20 nanometers, and the release says it is protected by more than 15 patent families. On OT-101, the company says it completed a Phase 1 trial with IL-2 in Seoul, South Korea, in March 2025 with no unexpected safety signals. The JV has initiated a Phase 2/3 trial for OT-101 in pancreatic cancer, and it is actively enrolling participants. Two subsidiaries of GMP Bio, Sapu Bio and Sapu Nano, were formalized during 2025. The company holds 45% equity interests in both. ## Financial position The XBRL data attached to the company's filings show research and development expense of $4,357 for fiscal 2025 and cash from operations of negative $1.4 million for the same year. For fiscal 2024 they show cash from operations of negative $740,277 and a net loss of $4.5 million. They also show cash and cash equivalents of $409,000 at September 30, 2025, from a 10-Q. The release states that operational costs for OT-101 and the nanoparticle platform are substantially covered by the JV, which the company says significantly reduces its direct financial burden until it decides to start developing its own compounds. ## What the profit does and does not mean The $249.0 million is an accounting entry, not money. It comes from a valuation of a private joint venture that sells no product, and the company itself says the increase does not represent cash received. The company's cash was $409,000 at September 30, 2025, it used $1.4 million in operating cash, and its general and administrative costs rose to $3,182,242. The science is early: the Phase 1 trial reported no unexpected safety signals but the release gives no efficacy data, and the OT-101 Phase 2/3 pancreatic trial is only enrolling. The release gives no dated milestone for the company itself beyond the 2026 IND filings. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story OTLC Oncotelic Therapeutics, Inc. OTC ยท United States Open the starter desk ## More in Company Updates Company Updates ### [PTC reports third-quarter 2026 revenue of $358 million and raises product guidance](https://aibio.space/news/ptc-reports-third-quarter-2026-revenue-358-million-raises-product/) Oct 29, 2026 Company Updates ### [Processa clears VT-7208 CSU IND and names a new executive chair](https://aibio.space/news/processa-clears-vt-7208-csu-ind-names-new-executive-chair/) Oct 29, 2026 Company Updates ### [Kiora in-licenses late-stage KIO-401 for retinal artery occlusion](https://aibio.space/news/kiora-licenses-late-stage-kio-401-retinal-artery-occlusion/) Oct 29, 2026 --- Source page: https://aibio.space/news/oncotelic-reports-249-0-million-2025-profit-non-cash-joint-venture/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Oncotelic reports $249.0 million 2025 profit that is a non-cash joint venture", 2026-04-16, https://aibio.space/news/oncotelic-reports-249-0-million-2025-profit-non-cash-joint-venture/